Determination of residual Kryptofix 2.2.2 levels in [18F]-labeled radiopharmaceuticals for human use.
Peter J H Scott, Michael R Kilbourn
Index: Appl. Radiat. Isot. 65(12) , 1359-62, (2007)
Full Text: HTML
Abstract
4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptofix 2.2.2) is used in the routine preparation of [18F]-labeled tracers employed in positron emission tomography (PET) imaging. Confirming the absence of Kryptofix in radiopharmaceuticals is a quality control criterion required before they can be released for human use. Analysis of Kryptofix levels using the iodoplatinate spot-test can be complicated by false-positive results due to nitrogen containing tracers and/or false-negative results caused by added stabilizers. To overcome this issue, we have developed a universal TLC method for the rapid and reliable determination of Kryptofix levels in the wide range of fluorine-18 radiopharmaceuticals we prepare, including complex multi-component formulations.
Related Compounds
Related Articles:
1998-06-02
[Bioorg. Med. Chem. Lett. 8(11) , 1317-20, (1998)]
2008-02-01
[Nucl. Med. Biol. 35(2) , 239-44, (2008)]
1986-01-01
[J. Membr. Biol. 89(3) , 251-67, (1986)]
Cation radius effects on the helix-coil transition of DNA. Cryptates and other large cations.
1990-04-01
[Biophys. J. 57(4) , 829-34, (1990)]
2005-08-26
[J. Chromatogr. A. 1085(1) , 33-6, (2005)]